6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF

WIPO Patent Application WO/2024/016826

A1

The present invention relates to the field of organic synthetic medicines, and in particular, to a 6-position substituted 3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compound, having a general formula as follows: (I). The 6-position substituted 3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compound can be used as a positive allosteric modulator of an AMPA receptor, and it is confirmed that the compound can positively regulate the AMPA receptor, such that the conformation of an agonist (such as endogenous neurotransmitter glutamic acid) after binding to the receptor is more stable, thereby reducing the inactivation rate of the receptor, inhibiting the desensitization of the receptor, and enhancing the function of the AMPA receptor.

LI TAO (CN)
QI XUEYU (CN)
YU XUELI (CN)
WEI LONG (CN)

PCT/CN2023/095562

January 25, 2024

May 22, 2023

Click for automatic bibliography generation  

HANGZHOU SEVENTH PEOPLES HOSPITAL (CN)

C07D291/08; A61K31/5415; A61P25/00; A61P25/16; A61P25/18; A61P25/24; A61P25/28; C07D419/04; C07D419/10

CN111559990A	2020-08-21
CN111518058A	2020-08-11
CN115232090A	2022-10-25

WEI LONG, QI XUEYU, YU XUELI, ZHENG YANGHAO, LUO XING, WEI YINGYING, NI PEIYAN, ZHAO LIANSHENG, WANG QIANG, MA XIAOHONG, DENG WEI,: "3,4-Dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide analogs act as potential AMPA receptor potentiators with antidepressant activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 251, 1 May 2023 (2023-05-01), AMSTERDAM, NL , pages 115252, XP093130746, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2023.115252

CHENGDU JUNHEJI PATENT OFFICE (ORDINARY PARTNERSHIP) et al. (CN)

View/Download PDF      PDF Help

Previous Patent: COMMUNICATION CHIP AND DATA SWITCHING APPARATUS

Next Patent: MANUFACTURING DEVICE AND METHOD FOR INOCULATING ARTIFICIAL GRAPHITE NEGATIVE ELECTRODE MATERIALS IN ...